Evidence map›Paper›PMID 41913938›Full record

ArticleCancer reports (Hoboken, N.J.)2026

A Case of Immunotherapy Response to BRAF

Yusuke Okayama, Takaaki Tokito, Shizuka Shiraishi, Reiko Takaki, Shingo Tsuneyoshi, Hiroyoshi Yamada, Mamoru Nishiyama, Yoshiko Sueyasu, Tomoaki Hoshino

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yusuke OkayamaDepartment of Respiratory Medicine, Saiseikai Futsukaichi Hospital, Chikushino, Fukuoka, Japan.
Takaaki TokitoDivision of Respirology, Neurology, and Rheumatology, Kurume University Hospital, Kurume, Fukuoka, Japan.ORCID 0000-0002-8429-2287
Shizuka ShiraishiDivision of Respirology, Neurology, and Rheumatology, Kurume University Hospital, Kurume, Fukuoka, Japan.
Reiko TakakiDivision of Respirology, Neurology, and Rheumatology, Kurume University Hospital, Kurume, Fukuoka, Japan.
Shingo TsuneyoshiDivision of Respirology, Neurology, and Rheumatology, Kurume University Hospital, Kurume, Fukuoka, Japan.
Hiroyoshi YamadaDivision of Respirology, Neurology, and Rheumatology, Kurume University Hospital, Kurume, Fukuoka, Japan.
Mamoru NishiyamaDepartment of Respiratory Medicine, Saiseikai Futsukaichi Hospital, Chikushino, Fukuoka, Japan.
Yoshiko SueyasuDepartment of Respiratory Medicine, Saiseikai Futsukaichi Hospital, Chikushino, Fukuoka, Japan.
Tomoaki HoshinoDivision of Respirology, Neurology, and Rheumatology, Kurume University Hospital, Kurume, Fukuoka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe recommended first-line therapy for BRAF V600E mutant non-small cell lung cancer (NSCLC) is a combination of dabrafenib and trametinib. Most patients respond to the initial therapy, but some show resistance in the early stages. Additionally, immune checkpoint inhibitors (ICIs) are often used after resistance develops; however, the benefits of ICIs in patients with BRAF V600E mutant NSCLC remain unclear. CASE PRESENTATION: We report a case of a 67-year-old man who was clinically diagnosed with lung adenocarcinoma cT2aN3M1c (BRA) stage IVB (BRAF V600E mutation-positive, programmed death-ligand 1; 90%). The patient developed early resistance to the combination of dabrafenib and trametinib but responded well to ICI.

conclusionThis case suggests that ICI may provide durable clinical benefit even after early resistance to BRAF/MEK inhibition in selected patients with high PD-L1 expression.

Indexed as

Adenocarcinoma of LungAntineoplastic Combined Chemotherapy ProtocolsDrug Resistance, NeoplasmImmune Checkpoint InhibitorsLung NeoplasmsAgedHumansImidazolesMaleMutationOximesProto-Oncogene Proteins B-rafPyridonesPyrimidinonesBRAF protein, humandabrafenibImidazolesImmune Checkpoint InhibitorsOximesProto-Oncogene Proteins B-rafPyridonesPyrimidinonestrametinibBRAF V600Edabrafenibimmune checkpoint inhibitorPD‐L1trametinib

Identifiers

PMID41913938
PMCPMC13140990

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.